

REMARKS

Responsive to the Communication dated January 15, 2004, Applicants submit herewith a copy of the sequence listing, along with a computer readable form of sequence listing, and amendments to the specification to correct inadvertent misreference and missing reference to sequence identifier SEQ ID NO:10.

Applicants submit the majority sequence depicted in FIG 3 was submitted in the original sequence listing upon filing of the application. Applicants submit the amendment filed herewith to correctly reference the sequence identifier in the description of the figures and the specification.

As the sequence listing filed herewith is identical to the original sequence listing, and the amendments merely correct misreference, no new matter is added by virtue of this submission.


This paper is being filed timely as a request for a one month extension of time is filed concurrently herewith. No additional extensions of time are required. In the event any additional extensions of time are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.

Entry of the remarks made herein is respectfully requested.

15 March 2004

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

By 
Kerri Pollard Schray
Registration No. 47,066
40 Landsdowne Street
Cambridge, MA 02139
Telephone - 617-551-3676
Facsimile - 617-551-8820